SCHEMBL377350

SCHEMBL377350

CC(=O)c1cccc(C(F)(F)F)c1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.51
TAS1R3 Q7RTX0 1/20 0.50
TAS1R1 Q7RTX1 1/20 0.50
TAS1R2 Q8TE23 1/20 0.50
KAT6A Q92794 2/20 0.49
HDAC8 Q9BY41 1/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
CNR1 P21554 3/20 0.43
CNR2 P34972 3/20 0.43
TAS2R14 Q9NYV8 1/20 0.43
P2RX7 Q99572 1/20 0.43
GPBAR1 Q8TDU6 1/20 0.42
KCNK3 O14649 2/20 0.42
KCNK9 Q9NPC2 2/20 0.42
PTGS1 P23219 1/20 0.42
CBLB Q13191 1/20 0.41
PDK2 Q15119 1/20 0.41
NOTUM Q6P988 1/20 0.41
EPHX2 P34913 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29723227 1.00 CTSS (0.51) CTSSTAS1R3TAS1R1TAS1R2KAT6A
SCHEMBL30991077 0.87 CTSS (0.48) CTSSTAS1R3TAS1R1TAS1R2KAT6A
SCHEMBL21132665 0.87 PDK2 (0.41) CTSSTAS1R3TAS1R1TAS1R2KAT6A
SCHEMBL29092859 0.85 PTGS1 (0.40) CTSSTAS1R3TAS1R1TAS1R2KAT6A
SCHEMBL19726595 0.85 CA2 (0.43) CTSSTAS1R3TAS1R1TAS1R2KAT6A
SCHEMBL28188796 0.84 KAT6A (0.51) CTSSTAS1R3TAS1R1TAS1R2KAT6A
SCHEMBL23412079 0.83 PDK2 (0.41) CTSSTAS1R3TAS1R1TAS1R2KAT6A
SCHEMBL29723392 0.83 PDK2 (0.41) CTSSTAS1R3TAS1R1TAS1R2KAT6A
SCHEMBL398909 0.82 KAT6A (0.54) CTSSTAS1R3TAS1R1TAS1R2KAT6A
SCHEMBL9560994 0.82 KAT6A (0.50) CTSSTAS1R3TAS1R1TAS1R2KAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4667464-A1 AZOLYLPYRIDINE PYRIDAZINONE AMIDE AS SOS1 INHIBITOR Cyrus Therapeutics Inc. (KR) 2025-12-24 EP disclosed
EP-4081521-B1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LTD (IN) 2025-12-10 EP disclosed
US-12435066-B2 Substituted tricyclic compounds LUPIN LIMITED (IN) 2025-10-07 US disclosed
WO-2024172632-A1 AZOLYLPYRIDINE PYRIDAZINONE AMIDE AS SOS1 INHIBITOR (주) 사이러스테라퓨틱스 2024-08-22 WO disclosed
US-20240261417-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2024-08-08 US disclosed
CN-114746411-B Substituted tricyclic compounds 印度鲁宾有限公司 2024-06-25 CN disclosed
CN-115605476-B Substituted tricyclic compounds 鲁宾有限公司 2024-05-24 CN disclosed
EP-4328219-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) 2024-02-28 EP disclosed
EP-4328219-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) 2024-02-28 EP disclosed
EP-4065575-B1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LTD (IN) 2024-01-31 EP disclosed
WO-2009013354-A1 ARYLMETHYLENE SUBSTITUTED N-ACYL-β-AMINO ALCOHOLS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-29 WO disclosed
WO-2008087365-A2 SUBSTITUTED 1, 3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES OF SAME GENFIT (FR) 2008-07-24 WO disclosed
US-20080076771-A1 Thrombopoietin Receptor Agonists REITER LAWRENCE A 2008-03-27 US disclosed
CN-101031549-A As specific alpha24- (phenylmethyl and substituted phenylmethyl) -imidazole-2-thiones as adrenergic agonists ALLERGAN INC (US) 2007-09-05 CN disclosed
EP-1797043-A1 4-(PHENYLMETHYL AND SUBSTITUTED PHENYLMETHYL)-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC ALPHA2 ADRENERGIC AGONISTS Allergan, Inc. (US) 2007-06-20 EP disclosed
EP-1794156-A2 TROMBOPOIETIN RECEPTOR AGONISTS Pfizer Products Incorporated (US) 2007-06-13 EP disclosed
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma PHARMACIA CORPORATION 2007-04-05 US disclosed
WO-2007004038-A1 AMINOTHIAZOLE DERIVATIVES AS AGONISTS OF THE THROMBOPOIETIN RECEPTOR PFIZER PRODUCTS INC. (US) 2007-01-11 WO disclosed
WO-2006036480-A1 4-(PHENYLMETHYL AND SUBSTITUTED PHENYLMETHYL)-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC ALPHA2 ADRENERGIC AGONISTS ALLERGAN, INC. (US) 2006-04-06 WO disclosed
WO-2006033005-A2 THROMBOPOIETIN RECEPTOR AGONISTS PFIZER PRODUCTS INC. (US) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma MAPK1, MAPK3, MAPK4 CTSS 3103/4885TAS1R3 3547/4885TAS1R1 3075/4885
US-20240261417-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF RAC1, SOS1, RSU1 CTSS 438/4885TAS1R3 4819/4885TAS1R1 4654/4885
US-20080076771-A1 Thrombopoietin Receptor Agonists MPL, THPO, TBXA2R CTSS 3979/4885TAS1R3 1642/4885TAS1R1 1367/4885
US-12435066-B2 Substituted tricyclic compounds SOS1, RSU1, KSR1 CTSS 751/4885TAS1R3 3521/4885TAS1R1 1900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.